<DOC>
	<DOCNO>NCT01009060</DOCNO>
	<brief_summary>This study aim evaluate cognitive enhancing effect tolerability GSK239512 compare placebo patient schizophrenia</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety GSK239512 Schizophrenia</brief_title>
	<detailed_description>This 7-week , Phase II , multi-centre , randomise , double-blind , placebo-controlled , parallel group design study male female subject schizophrenia stabilise antipsychotic medication . Subjects randomise receive either GSK239512 placebo 7 week . They undergo weekly review safety , tolerability cognitive performance measure .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Clinical diagnosis Schizophrenia 2 . No acute exacerbation symptom require hospital admission step care previous six month . 3 . Not symptomatic treatment cognition 1 . Poses significant homicidal suicidal risk evidence previous homicidal suicidal risk . 2 . Comorbid psychiatric significant physical illness 3 . Alcohol drug abuse dependence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>H3 Antagonist</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>double blind</keyword>
	<keyword>Histamine</keyword>
	<keyword>randomise</keyword>
	<keyword>placebo control</keyword>
	<keyword>Cognition</keyword>
</DOC>